Genetics and modifier genes, atypical and rare forms;Génétique et gènes modificateurs, formes atypiques et rares

Archives de Pediatrie

Volumn 19, Issue SUPPL.1, 2012, Pages

  Ferec C ^a,b   Scotet, V ^b   Beucher, J ^c,d   Corvol, H ^c  

^a CHU MORVAN   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUCASIAN; CFTR GENE; CYSTIC FIBROSIS; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MODIFIER GENE; MOLECULAR CLONING; PATHOPHYSIOLOGY;

CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION;

EID: 84862026258     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(12)71099-0     Document Type: Article

References (44)

1. Rommens J.M., Iannuzzi M.C., Kerem B., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
2. Vanscoy L.L., Blackman S.M., Collaco J.M., et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:1036-1043.
3. Anderson M.P., Gregory R.J., Thompson S., et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991, 253:202-204.
4. Tsui LC. Cystic Fibrosis Mutation Database. on ca 2011. http://www%20genetsickkids/.
5. Shoshani T., Augarten A., Gazit E., et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992, 50:222-228.
6. Férec C., Audrézet M.P., Mercier B., et al. Detection of over 98% cystic fibrosis mutations in a Celtic population. Nat Genet 1992, 1:188-191.
7. Le Maréchal C., Audrézet M.P., Quéré I., et al. Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromotography (D-HPLC): major implications for genetic counselling. Hum Genet 2001, 108:290-298.
8. Audrézet M.P., Dabricot A., Le Maréchal C., et al. Validation of highresolution DNA melting analysis for mutation scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. J Mol Diagn 2008, 10:424-434.
9. Audrézet M.P., Chen J.M., Raguénès O., et al. Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms. Hum Mutat 2004, 23:343-357.
10. Niel F., Legendre M., Bienvenu T., et al. A new large CFTR rearrangement illustrates the importance of searching for complex alleles. Hum Mutat 2006, 27:716-717.
11. Férec C., Casals T., Chuzhanova N., et al. Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms. Eur J Hum Genet 2006, 14:567-576.
12. Quemener S., Chen J.M., Chuzhanova N., et al. Complete ascertainment of intragenic copy number mutations (CNMs) in the CFTR gene and its implications for CNM formation at other autosomal loci. Hum Mutat 2010, 31:421-428.
13. Welsh M.J., Smith A.E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73:1251-1254.
14. Kerem E., Corey M., Kerem B.S., et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (DF508). N Engl J Med 1990, 323:1517-1522.
15. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993, 329:1308-1313. Cystic Fibrosis Genetic Analysis Consortium.
16. Bombieri C., Claustres M., De Boeck K., et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011, 10:S86-S102.
17. Dumur V., Gervais R., Rigot J.M., et al. Abnormal distribution of CF delta F508 allele in azoospermic men with congenital aplasia of epididymis and vas deferens. Lancet 1990, 336:512.
18. Chillon M., Casals T., Mercier B., et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995, 332:1475-1480.
19. Mercier B., Verlingue C., Lissens W., et al. Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR Gene in 67 Patients. Am J Hum Genet 1995, 56:272-277.
20. Handyside A.H. Preimplantation genetic diagnosis after 20 years. Reprod Biomed Online 2010, 21:280-282.
21. Cutting G.R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 2010, 1214:57-69.
22. Kerem E., Reisman J., Corey M., et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992, 326:1187-1191.
23. Schluchter M.D., Konstan M.W., Davis P.B. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002, 21:1271-1287.
24. Corvol H., Boelle P.Y., Brouard J., et al. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol 2008, 43:1224-1232.
25. Drumm M.L., Konstan M.W., Schluchter M.D., et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005, 353:1443-1453.
26. Bremer L.A., Blackman S.M., Vanscoy L.L., et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet 2008, 17:2228-2237.
27. Davies J.C., Turner M.W., Klein N. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004, 24:798-804.
28. Gabolde M., Guilloud-Bataille M., Feingold J., et al. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 1999, 319:1166-1167.
29. Hillian A.D., Londono D., Dunn J.M., et al. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun 2008, 9:501-508.
30. Brouard J., Knauer N., Boelle P.Y., et al. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005, 191:1988-1991.
31. Flamant C., Henrion-Caude A., Boelle P.Y., et al. Glutathione-Stransferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 2004, 14:295-301.
32. Hull J., Thomson A.H. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998, 53:1018-1021.
33. Mackie A.D., Thornton S.J., Edenborough F.P. Cystic fibrosis-related diabetes. Diabet Med 2003, 20:425-436.
34. Blackman S.M., Hsu S., Ritter S.E., et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009, 52:1858-1865.
35. Blackman S.M., Deering-Brose R., McWilliams R., et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006, 131:1030-1039.
36. Zielenski J., Corey M., Rozmahel R., et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999, 22:128-129.
37. Rozmahel R., Wilschanski M., Matin A., et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996, 12:280-287.
38. van der Doef H.P., Slieker M.G., Staab D., et al. Association of the CLCA1 p. S357N variant with meconium ileus in European patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010, 50:347-349.
39. Dorfman R., Li W., Sun L., et al. Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet 2009, 126:763-778.
40. Lamireau T., Monnereau S., Martin S., et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004, 41:920-925.
41. Henrion-Caude A., Flamant C., Roussey M., et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002, 36:913-917.
42. Bartlett J.R., Friedman K.J., Ling S.C., et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009, 302:1076-1083.
43. Wright F.A., Strug L.J., Doshi V.K., et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011, 43:539-546.
44. Collaco J.M., Vanscoy L., Bremer L., et al. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 2008, 299:417-424.